Active Pharmaceutical Ingredients (API) Market Growth & Trends

The global active pharmaceutical ingredients (API) market is expected to reach a valuation of USD 359.45 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.85% from 2025 to 2030, according to a recent report by Grand View Research, Inc. This growth is primarily driven by the rapid expansion of the biopharmaceutical sector, continuous technological advancements in API manufacturing, and the rising aging population, which is leading to a greater demand for pharmaceuticals globally.

One of the key growth drivers is the increasing investment in captive API production, where pharmaceutical companies focus on developing in-house manufacturing capabilities. By doing so, companies can reduce costs, ensure quality control, and mitigate the risk of contamination associated with outsourcing. Advances in artificial intelligence (AI) and protein synthesis technologies are further streamlining API development, offering faster, more efficient production cycles with enhanced precision and reliability.

The rising global prevalence of chronic and lifestyle-related diseases, such as cardiovascular disorders, is another major factor propelling market demand. For example, according to data published by U.S. Pharmacist in 2020, approximately 47% of adults possess at least one risk factor that contributes to the onset of cardiovascular disease. The growing health burden of such conditions is spurring significant R&D investments aimed at developing more effective APIs to support long-term treatment regimens.

The COVID-19 pandemic further highlighted the strategic importance of APIs. During the pandemic, many countries and pharmaceutical companies ramped up production efforts to meet the urgent demand for treatments. The crisis led to a shift in business strategies, where companies began to target broader patient populations and restructured their supply chains. For instance, in an effort to procure hydroxychloroquine (HCQ) for COVID-19 treatment, the U.S. requested bulk imports from India. Similarly, Canada’s drug supply system experienced disruptions that raised concerns about access to essential medications.

Several long-term market drivers include the growing popularity of generic drugs, the surging consumption of biopharmaceuticals, and the expanding scope of drug research and development activities. However, the market faces challenges such as strict drug pricing regulations in certain countries and the high cost of API production, both of which could pose constraints to rapid market expansion.

Emerging economies, particularly India, are gaining prominence as preferred destinations for API manufacturing. This shift is partly due to ongoing geopolitical tensions involving other key players like China, which has traditionally dominated the market. India, on the other hand, benefits from abundant raw materials, skilled labor, robust distribution networks, and supportive government initiatives such as the "Make in India" campaign, which aims to strengthen domestic manufacturing capabilities.

To meet unmet clinical needs and boost supply chains, pharmaceutical companies are increasingly engaging in strategic collaborations and acquisitions. For example, in November 2021, Merck & Co., Inc. acquired Acceleron Pharma, a move that is expected to bolster Merck’s cardiovascular drug portfolio and enhance its R&D pipeline in that therapeutic area.

Active Pharmaceutical Ingredients Market Report Highlights

• Innovative APIs held the largest market share of 62.0% in 2024, largely driven by a surge in research and development efforts aimed at discovering novel drug compounds, along with supportive government initiatives to foster pharmaceutical innovation.
• The captive API segment accounted for 51.03% of the market share in 2024, reflecting the increasing trend of companies bringing API manufacturing in-house to ensure quality, cost efficiency, and better regulatory compliance.
• Synthetic APIs dominated the market with a revenue share of 70.66% in 2024, due to the readily available raw materials, scalability, and established synthesis protocols, making them a preferred choice for many pharmaceutical manufacturers.
• North America led the global market, capturing a revenue share of 38.26% in 2024. The region’s dominance is attributed to the high prevalence of cancer, chronic illnesses, and lifestyle-related diseases, which are intensifying the need for advanced R&D and sustained pharmaceutical innovation.

Get a preview of the latest developments in the Active Pharmaceutical Ingredients Market? Download your FREE sample PDF copy today and explore key data and trends

Active Pharmaceutical Ingredients Market Segmentation

Grand View Research has segmented the global active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, application, type of drug, and region:

Active Pharmaceutical Ingredients Type of Synthesis Outlook (Revenue, USD Billion, 2018 - 2030)

• Biotech 
  • Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
    • Generic APIs
    • Innovative APIs 
  • Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Recombinant Proteins
    • Therapeutic Enzymes
    • Vaccines
    • Blood Factors
  • Synthetic 
    • Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
      • Generic APIs
      • Innovative APIs

Active Pharmaceutical Ingredients Type of Manufacturer Outlook (Revenue, USD Billion, 2018 - 2030)

• Captive APIs
• Merchant APIs

Active Pharmaceutical Ingredients Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Generic APIs
• Innovative APIs

Active Pharmaceutical Ingredients Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Cardiovascular Diseases
• Oncology
• CNS and Neurology
• Orthopedic
• Endocrinology
• Pulmonology
• Gastroenterology
• Nephrology
• Ophthalmology
• Others

Active Pharmaceutical Ingredients Type of Drug Outlook (Revenue, USD Billion, 2018 - 2030)

• Prescription
• OTC

Active Pharmaceutical Ingredients Regional Outlook (Revenue, USD Billion, 2018- 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Players in the Active Pharmaceutical Ingredients Market

• Reddy’s Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• AbbVie Inc.
• Aurobindo Pharma
• Sandoz International GmbH (Novartis AG)
• Viatris Inc.
• Fresenius Kabi AG
• STADA Arzneimittel AG

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.